CVRx (NASDAQ:CVRX) Stock Rating Lowered by Wall Street Zen

CVRx (NASDAQ:CVRX – Get Free Report) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Sunday, Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. Lake Street Capital dropped their target price on shares of CVRx from $3.50 to $1.50 and set a “hold” rating on the stock in a research note on Friday, November 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a research note on Friday, October 30th. Craig Hallum lowered CVRx from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Friday, August 7th. Canaccord Genuity Group cut CVRx from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $5.00 to $2.00 in a research note on Friday, November 6th. Finally, Cantor Fitzgerald dropped their price objective on CVRx from $13.00 to $5.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, CVRx has an average rating of “Hold” and an average price target of $2.70.

Read Our Latest Stock Analysis on CVRx

CVRx Stock Up 0.9%

Shares of CVRX opened at $0.61 on Friday. The firm has a market capitalization of $17.46 million, a P/E ratio of -0.30 and a beta of 0.81. CVRx has a 12-month low of $0.57 and a 12-month high of $10.28. The company has a current ratio of 6.80, a quick ratio of 5.71 and a debt-to-equity ratio of 4.24. The firm has a fifty day moving average price of $1.80 and a 200-day moving average price of $4.97.

CVRx (NASDAQ:CVRX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.02). CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. The company had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $13.93 million. Equities research analysts expect that CVRx will post -2.04 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Jump Financial LLC boosted its stake in shares of CVRx by 26.0% during the third quarter. Jump Financial LLC now owns 97,673 shares of the company’s stock valued at $171,000 after purchasing an additional 20,173 shares in the last quarter. Empowered Funds LLC purchased a new position in CVRx during the third quarter valued at approximately $63,000. First Eagle Investment Management LLC purchased a new position in CVRx during the third quarter valued at approximately $386,000. Russell Investments Group Ltd. raised its stake in CVRx by 2,137.6% in the third quarter. Russell Investments Group Ltd. now owns 100,937 shares of the company’s stock worth $177,000 after buying an additional 96,426 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in CVRx in the third quarter worth approximately $87,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.

Top CVRx Stories

Investors following CVRX have been watching these stories:

  • Neutral Sentiment: Cantor Fitzgerald lowered its price target to $2 while retaining an Overweight rating. That target remains well above the stock’s cited $0.61 price, though the reduction itself reflects a less optimistic valuation outlook. Cantor Fitzgerald rating information
  • Negative Sentiment: Several law firms publicized a pending securities class action for investors who bought CVRx shares from July 25, 2023, through August 6, 2026; the lead-plaintiff deadline is January 8, 2027. The lawsuit alleges that company disclosures omitted risks involving Barostim, kickbacks, and the False Claims Act. One alert also points to a reported Department of Justice investigative demand, sharp revenue-guidance cuts, sales-force disruption, and the termination of the chief revenue officer. These are allegations and reported circumstances, not findings of liability, but they may weigh on investor confidence. Hagens Berman investor alert

CVRx Company Profile

(Get Free Report)

CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.

Further Reading

Analyst Recommendations for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.